New drug VIS171 tested for lupus, hair loss, and kidney disease

NCT ID NCT06799520

First seen Nov 01, 2025 · Last updated Jun 05, 2026 · Updated 31 times

Summary

This early-stage trial tests the safety of a new drug called VIS171 in 30 people with autoimmune diseases like lupus, alopecia areata, or a kidney condition. Participants receive the drug as a shot under the skin along with their usual treatments. The study lasts up to a year and focuses on side effects and how the drug affects immune cells.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Visterra Investigational Site

    RECRUITING

    Sofia, 1404, Bulgaria

  • Visterra Investigational Site

    RECRUITING

    Chisinau, MD-2025, Moldova

  • Visterra Investigational Site

    RECRUITING

    Bucharest, 11658, Romania

  • Visterra Investigational Site

    RECRUITING

    Cluj-Napoca, 40006, Romania

  • Visterra Investigational Site

    NOT_YET_RECRUITING

    Barcelona, 8035, Spain

  • Visterra Investigational Site

    NOT_YET_RECRUITING

    Granada, 18014, Spain

Conditions

Explore the condition pages connected to this study.